Summary
Company the industry analysis specialist, has released its new report, “Small Cell Lung Cancer (SCLC) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global SCLC therapeutics market, identifying the key trends shaping and driving the market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global SCLC therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Companys team of industry experts.
Companys analysis estimated the small cell lung cancer (SCLC) therapeutics market to be worth $277.8m in 2010. It is forecast to grow at a compound annual growth rate (CAGR) of 3.4% over the next eight years to reach $362.3m in 2018. The growth during 2005-2010 was primarily attributed to the launch of an oral form of Hycamtin (topotecan). The steady growth rate during the forecast period is attributed to the expected launch of Amrubicin (SM-5887) in the US and Europe for the treatment of relapse/refractory SCLC patients, as well as a weak late stage pipeline with no molecules to treat newly diagnosed patients.
Scope
The report provides information on the key drivers and challenges of the SCLC therapeutics market. Its scope includes -
- Annual data on the seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) for SCLC therapeutics, with historic data from 2005 to 2010 and forecasts to 2018.
- Pipeline analysis data providing information on the different phases of development, mechanisms of action and emerging trends. Pipeline candidates for SCLC fall under major therapeutic classes such as topoisomerase II inhibitors, Pan Bcl-2 inhibitors, topoisomerase I inhibitors, IGF-R1 inhibitors/hedgehog pathway inhibitors, and tyrosine kinase inhibitors.
- Analysis of the current and future competition in the global SCLC market is provided. The key market players covered are Celgene Corporation and Cephalon Inc.
- An insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics coverage, including strategic a competitor assessment, market characterization and unmet needs analysis, as well as their implications for the SCLC therapeutics market.
- Analysis of key recent licensing and partnership agreements in the SCLC therapeutics market.
For more information, please visit:
http://www.aarkstore.com/reports/Small-Cell-Lung-Cancer-SCLC-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2018-155493.html
Or email us at contact@aarkstore.com or call +918149852585
Aarkstore Enterprise
Tel : +912227453309
Mobile No:+08149852585
Email : contact@aarkstore.com
Website : http://www.aarkstore.com
Blog: http://www.emarketreports.com
Follow us on twitter: http://twitter.com/aarkstoredotcom
http://in.linkedin.com/in/aarkstore
http://www.facebook.com/aarkstoreenterprise
Company the industry analysis specialist, has released its new report, “Small Cell Lung Cancer (SCLC) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global SCLC therapeutics market, identifying the key trends shaping and driving the market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global SCLC therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Companys team of industry experts.
Companys analysis estimated the small cell lung cancer (SCLC) therapeutics market to be worth $277.8m in 2010. It is forecast to grow at a compound annual growth rate (CAGR) of 3.4% over the next eight years to reach $362.3m in 2018. The growth during 2005-2010 was primarily attributed to the launch of an oral form of Hycamtin (topotecan). The steady growth rate during the forecast period is attributed to the expected launch of Amrubicin (SM-5887) in the US and Europe for the treatment of relapse/refractory SCLC patients, as well as a weak late stage pipeline with no molecules to treat newly diagnosed patients.
Scope
The report provides information on the key drivers and challenges of the SCLC therapeutics market. Its scope includes -
- Annual data on the seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) for SCLC therapeutics, with historic data from 2005 to 2010 and forecasts to 2018.
- Pipeline analysis data providing information on the different phases of development, mechanisms of action and emerging trends. Pipeline candidates for SCLC fall under major therapeutic classes such as topoisomerase II inhibitors, Pan Bcl-2 inhibitors, topoisomerase I inhibitors, IGF-R1 inhibitors/hedgehog pathway inhibitors, and tyrosine kinase inhibitors.
- Analysis of the current and future competition in the global SCLC market is provided. The key market players covered are Celgene Corporation and Cephalon Inc.
- An insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics coverage, including strategic a competitor assessment, market characterization and unmet needs analysis, as well as their implications for the SCLC therapeutics market.
- Analysis of key recent licensing and partnership agreements in the SCLC therapeutics market.
For more information, please visit:
http://www.aarkstore.com/reports/Small-Cell-Lung-Cancer-SCLC-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2018-155493.html
Or email us at contact@aarkstore.com or call +918149852585
Aarkstore Enterprise
Tel : +912227453309
Mobile No:+08149852585
Email : contact@aarkstore.com
Website : http://www.aarkstore.com
Blog: http://www.emarketreports.com
Follow us on twitter: http://twitter.com/aarkstoredotcom
http://in.linkedin.com/in/aarkstore
http://www.facebook.com/aarkstoreenterprise
No comments:
Post a Comment